BioLife Solutions (BLFS) Peer Comparison

$37.00

$-0.22 (-0.59%)

As on 26-Aug-2026 16:00EDT

Market cap

$1,814 Mln

Revenue (TTM)

$103 Mln

P/E Ratio

37.1

P/B Ratio

4.3

Div. Yield

0 %

Edit

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	1,814	12,753	10,906	9,762	10,222
Revenue ($ Mln)	103	1,505	613	2,589	785
Net Profit ($ Mln)	50.45	160.59	-188.05	222.40	41.54
Net Margin (%)	49.06	10.67	-30.68	8.59	5.29
RoE (%)	12.74	10.86	-28.10	3.04	1.97
Price to Earnings	37.10	79.35	--	44.47	251.57
Price-To-Book	4.30	8.41	16.38	1.26	4.84

Income Statement ($ Mln)

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	102.82	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	36.52	483.98	127.96	1,245.50	384.30
Gross Profit	62.12	942.44	393.22	1,343.60	347.62
Operating Expenses	58.84	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	7.45	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	8.07	203.83	-192.83	350.40	52.15
Provision for Tax	-42.38	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	50.45	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	420.00	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	13.54	210.18	135.71	2,116.80	705.49
Current Liabilities	13.95	233.78	102.33	961.30	132.66
Total Liabilities	405.88	1,826.52	893.49	10,576.50	2,949.70

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	312.30	630.60	404.74	7,231.50	1,749.63
Current Assets	135.20	1,344.12	515.78	3,020.50	1,200.55
Total Assets	405.88	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	15.74	212.71	102.84	1,203.70	690.94
Net Current Assets	121.25	1,110.35	413.45	2,059.20	1,067.90

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	20.12	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-71.54	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	-10.92	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-3.16	11.76	-22.53	8.98	1.79
ROE (%)	12.74	10.86	-28.10	3.04	1.97
ROA (%)	11.50	7.95	-18.00	2.02	1.36
EBIT Margin (%)	6.03	13.63	-30.58	-5.99	9.87
Net Margin (%)	49.06	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	34.39	17.55	41.55	1.37	16.49
EBIT Growth (%)	146.48	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	1,012.22	8.72	-102.66	-30.32	400.42
EPS Growth (%)	965.62	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	17.31	17.33	-12.65	2.19	2.16

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-96.97	68.93	-34.59	--	189.42
Price / Book Value	3.16	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	306.49	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.01	0.01	0.00	0.06	0.01
Current Ratio	9.69	5.75	5.04	3.14	9.05
Quick Ratio	7.14	3.86	4.46	2.33	7.64
Interest Coverage	13.22	157.91	-38.31	8.18	3.36

	BioLife Solutions (BLFS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	10.36	12.65	22.67	17.06	20.09
Asset Turnover	0.23	0.74	0.59	0.24	0.26
Receivable days	32.50	46.54	60.95	65.39	72.41
Inventory Days	316.92	331.92	193.84	221.09	146.53
Payable days	27.10	26.16	60.19	37.02	29.05
Cash Conversion Cycle	322.32	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.